Drugs / Lunsekimig
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT06914908 | May 2025 → Jan 2031 expected | chronic rhinosinusitis | Sanofi | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06790121 | Jan 2025 → Feb 2026 | atopic eczema | Sanofi | Completed | Missed primary |
| Phase 2 | NCT06676319 | Nov 2024 → Jun 2027 expected | asthma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06609239 | Sep 2024 → Jan 2031 expected | asthma | Sanofi | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06454240 | Jul 2024 → Jan 2026 | chronic rhinosinusitis | Sanofi | Completed | Met primary |
| Phase 2 | NCT06102005 | Oct 2023 → Feb 2026 | asthma | Sanofi | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT07793409 | Sep 2026 → Jul 2031 expected | chronic obstructive pulmonary disease | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT07190222 | Sep 2025 → Nov 2029 expected | chronic obstructive pulmonary disease | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT07190209 | Sep 2025 → Nov 2029 expected | chronic obstructive pulmonary disease | Sanofi | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-07 | Sanofi | Results Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP sanofi.com ↗
Phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-07 | Sanofi | Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP sanofi.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lunsekimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06914908 ↗ |
| Known as | SAR443765 | “Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma” NCT06676319 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314848 ↗ |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT06102005 ↗ |